VEGF选择性剪切的调控及其生物学意义被引量：1

导出

摘要血管生成是生物体生长发育的一种生理学过程,它可以促进机体中的血液供应量增加。它是当前癌症治疗的重要的靶向位点。血管内皮细胞生长因子(VEGF)是对血管生成起重要调控作用的一类效应因子,对它的靶向控制可以治疗癌症等疾病。它包括2种相拮抗作用的亚类,促血管生成内皮细胞生长因子(VEGFxxx)和抗血管生成内皮细胞生长因子(VEGFxxxb)。它们的成员和临床效果正逐渐被人们研究证实,本综述论述了VEGF的2类相反功能的亚类的结构特点和生物学特性,选择性剪切的调控通路和生物学意义。

作者郭泽武秦君芳倪虹

机构地区南开大学医学院

出处《生理科学进展》 CAS CSCD 北大核心 2012年第1期34-36,共3页 Progress in Physiological Sciences

基金国家自然科学基金(30772193) 中央高校基本科研业务费专项资金资助课题

关键词血管生成促血管内皮细胞生成因子抗血管内皮细胞生成因子癌症治疗

分类号 R730.1 [医药卫生—肿瘤] R730.5 [医药卫生—肿瘤]

引文网络
相关文献

参考文献14

1Niu G, XY Chen. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Current Drug Targets, 2010, 11 : 1000 - 1017.
2Blencowe B1. Alternative splicing: new insights from global analyses. Cell, 2006, 126 : 37 - 47.
3Ladomery MR, Harper SJ, Bates DO. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Letters, 2007, 249 : 133 - 142.
4Harper SJ, Nowak DG , Woolard J, et al. Expression of proand anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. Journal of Cell Science, 2008,121 : 3487 -3495.
5Harper SJ, Bates DO. VEGF -A splicing: the key to anti-angiogenic therapeutics? Nature Reviews Cancer, 2008, 8 : 880 - 887.
6Rosales-Torres AM, Alonso I, Vergara M, et al. Vascular endothelial growth factor isoforms 120, 164 and 205 are reduced with atresia in ovarian follicles of sheep. Animal Reproduction Science, 2010, 122 : 111 - 117.
7Miller DS, Rigor RR, Hawkins BT. Activation of PKC isoform beta( I) at the blood-brain barrier rapidly decreases Pglycoprotein activity and enhances drug delivery to the brain. J Cereb Blood Flow Metab, 2010, 30 : 1373 -1383.
8Nowak DG, Amin EM, Rennel ES, et al. Regulation of vascular endothelial growth factor (VEGF) splicing from proangiogenic to anti-angiogenic isoforms . a novel therapeutic strategy for angiogenesis. J Bioi Chern, 2010, 285 : 5532 - 5540.
9Onesto C, Berra E, Grepin R, et al. Poly ( A) -binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J Bioi Chern, 2004, 279 : 34217 - 34226.
10Eymin B, Merdzhanova G, Gout S, et al. The transcription factor E2Fl and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene, 201 0, 29 : 5392 - 5403.